We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 14

What the Supreme Court of Canada was not told about patent utility
  • Gowling WLG
  • Canada
  • May 11 2017

On November 8, 2016 the Supreme Court of Canada (“SCC”) heard an appeal by Astrazeneca regarding the validity of a patent covering its NEXIUM product


Federal Court deviates from established tests for patent listing Gilead Sciences, Inc. v. Canada (Health)
  • Gowling WLG
  • Canada
  • March 22 2016

In the decision summarized below, Apotex successfully obtained a dismissal of Gilead's application for a prohibition order in respect of Canadian


Changes at PMPRB to safeguard against excessively priced medicines
  • Gowling WLG
  • Canada
  • February 9 2016

Over the course of the next three years, PMPRB is seeking to change to its operations with the aim of becoming a more effective and stronger consumer


PM(NOC) regulation amendments now in force
  • Gowling WLG
  • Canada
  • June 30 2015

Industry Canada has now enacted the amendments to the Patented Medicines (Notice of Compliance) Regulations (Regulations) in order to permit claims


Industry Canada seeks comment on proposed changes to listing requirements under the PM(NOC) Regulations
  • Gowling WLG
  • Canada
  • May 6 2015

On May 2, 2015, the Governor in Council issued proposed amendments to Sections 2, 3, and 4 of the Patented Medicines (Notice of Compliance


Federal Court rejects NIA defence and awards compound interest on patent damages
  • Gowling WLG
  • Canada
  • January 24 2015

On Jan. 23, 2015, the Federal Court released its decision regarding the quantum of damages recoverable by Eli Lilly (“Lilly”) in an action relating


Federal court rejects PMPRB Copaxone decision on excessive prices again
  • Gowling WLG
  • Canada
  • May 3 2013

By a decision of Justice Zinn dated April 30, 2013, the Federal Court quashed a Board's decision on excessive pricing of Copaxone - for the second


Utility, sound prediction and promise of the patent
  • Gowling WLG
  • Canada
  • April 22 2013

In recent years, attacks on the lack of sound prediction and failure to meet the promise of the patent have proven to be a crushing hammer in the


Court affirms utility of Gleevec patent
  • Gowling WLG
  • Canada
  • February 20 2013

"Sound prediction's introduction into Canadian law was not, as I understand it, to give a crushing hammer to those who challenge patents." Snider J


Gilead Sciences Canada, Inc. v. Canada (Minister of Health), 2012 FC 2, Complera (tenofovir, emtricitabine and rilpivirine), patent listing decision
  • Gowling WLG
  • Canada
  • April 3 2012

In this case the Court accepted the Minister’s position that a patent with combination patent claims and formulation claims to a triple medicinal ingredient product was not eligible for listing